AU633251B2 - Therapeutic use of anti-t cell immunotoxin for autoimmune diseases - Google Patents

Therapeutic use of anti-t cell immunotoxin for autoimmune diseases Download PDF

Info

Publication number
AU633251B2
AU633251B2 AU32157/89A AU3215789A AU633251B2 AU 633251 B2 AU633251 B2 AU 633251B2 AU 32157/89 A AU32157/89 A AU 32157/89A AU 3215789 A AU3215789 A AU 3215789A AU 633251 B2 AU633251 B2 AU 633251B2
Authority
AU
Australia
Prior art keywords
cell
immunotoxin
disease
autoimmune disease
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32157/89A
Other languages
English (en)
Other versions
AU3215789A (en
Inventor
Richard C. Harmon
Patrick J. Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Royalty Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of AU3215789A publication Critical patent/AU3215789A/en
Application granted granted Critical
Publication of AU633251B2 publication Critical patent/AU633251B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU32157/89A 1988-02-03 1989-02-03 Therapeutic use of anti-t cell immunotoxin for autoimmune diseases Ceased AU633251B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15174488A 1988-02-03 1988-02-03
US151744 1988-02-03

Publications (2)

Publication Number Publication Date
AU3215789A AU3215789A (en) 1989-08-25
AU633251B2 true AU633251B2 (en) 1993-01-28

Family

ID=22540082

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32157/89A Ceased AU633251B2 (en) 1988-02-03 1989-02-03 Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Country Status (5)

Country Link
EP (1) EP0397798A4 (da)
JP (1) JPH03503887A (da)
AU (1) AU633251B2 (da)
DK (1) DK184890A (da)
WO (1) WO1989006968A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
EP0448635B1 (en) * 1988-12-13 1995-09-20 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
EP0463114B1 (en) * 1989-03-06 1996-05-15 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
IL98932A0 (en) * 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
IT1249051B (it) * 1991-02-26 1995-02-11 Italfarmaco Spa Immunotossina da anticorpi monoclonali anti-cd5
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
JP2002501484A (ja) 1997-03-05 2002-01-15 アメリカ合衆国 免疫毒素および免疫寛容を誘導する方法
AU3654499A (en) * 1998-04-22 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
CA3140447A1 (en) * 2019-06-05 2020-12-10 Anthony Boitano T-cell depleting therapies
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
EP0256471A3 (en) * 1986-08-15 1989-10-25 Xoma Corporation Cytotoxic conjugates for cancer therapy
DE3855236D1 (de) * 1987-08-17 1996-05-30 Us Commerce Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
EP0407399A4 (en) * 1988-02-03 1991-06-19 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy

Also Published As

Publication number Publication date
EP0397798A1 (en) 1990-11-22
AU3215789A (en) 1989-08-25
EP0397798A4 (en) 1991-10-30
DK184890D0 (da) 1990-08-02
DK184890A (da) 1990-10-03
JPH03503887A (ja) 1991-08-29
WO1989006968A1 (en) 1989-08-10

Similar Documents

Publication Publication Date Title
AU633251B2 (en) Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
US5547668A (en) Conjugates of folate anti-effector cell antibodies
ES2331644T3 (es) Inmunoterapia de trastornos autoinmunes usando anticuerpos cuya diana son celulas b.
US6096311A (en) Methods for use of monoclonal antibodies specific for the high affinity Fc receptor for immunoglobulin G
US4590071A (en) Human melanoma specific immunotoxins
ES2202310T3 (es) Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
DE69133326T2 (de) Verbesserte humanähnlich gemachte immunglobuline
DE3686313T2 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
EP0496818B1 (en) MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR
US5578706A (en) Methods and compositions concerning homogenous immunotoxin preparations
EP0303681B1 (en) Immunosuppression in immunotoxin based human therapy
CA2133838C (en) Immunotoxins directed against cd33 related surface antigens
EP0407399A1 (en) Immunosupression with anti-pan t-cell immunotoxin compositions
EP0226418B1 (en) Anti-human ovarian cancer immunotoxins and methods of use thereof
IL89953A (en) Pharmaceutical composition comprising anti-t cell immunotoxin for use in treating autoimmune disease
US20060051355A1 (en) Methods and means for the treatment of immune-related diseases
EP1066058B1 (en) Immunotoxin cocktails for the treatment of immune related diseases
WO1996038571A2 (en) Recombinant polypeptide cytotoxins for cancer treatment
Tazzari et al. An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells
EP0419462A1 (en) Improved immunotoxin therapies utilizing purified ricin a-chain species
Morgan Jr et al. Immunotoxins to a human melanoma-associated antigen: resistance to pokeweed antiviral protein conjugates in vitro
AU2122788A (en) Improved immunotoxin therapies utilizing purified ricin a-chain species
Fishwild Efficacy of an anti-CD5-ricin A chain immunoconjugate in an improved human peripheral blood lymphocyte--reconstituted severe combined immunodeficient mouse model